We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Non-coding Regions of the Genome in Microglia Linked to Alzheimer’s Disease Risk

By LabMedica International staff writers
Posted on 28 Nov 2019
A recently published paper linked risk of developing Alzheimer’s disease (AD) to enhancers - non-coding DNA regions of the genome - that were present in microglia but not in other types of brain cells such as neurons or astrocytes.

In genetics, an enhancer is a short (50–1500 base pair) region of DNA that can be bound by proteins (activators) to increase the likelihood that transcription of a particular gene will occur. More...
Enhancers can be located up to one million base pairs away from the target gene, upstream or downstream from the start site. There are hundreds of thousands of enhancers in the human genome.

Investigators at the University of California, San Diego (USA) isolated four different kinds of brain cells: neurons, microglia, oligodendrocytes, and astrocytes from six AD patients. The genes in these cells were examined for genetic variations associated with the disease in non-coding enhancer regions of each cell type.

Results revealed that while psychiatric disorders were primarily associated with variants in transcriptional enhancers and promoters in neurons, sporadic AD variants were largely confined to microglia enhancers. Interactome maps (maps of the whole set of molecular interactions in a particular cell) connected disease-risk variants in cell type-specific enhancers to promoters in an extended microglia gene network in AD.

Microglia are a type of neuroglia located throughout the brain and spinal cord. Microglia account for 10 to 15% of all cells found within the brain. As the resident macrophage cells, they act as the first and main form of active immune defense in the central nervous system.

Employing pluripotent human stem cells, the investigators were able to target an enhancer region near BIN1, a gene previously been linked to AD. They found that deleting this enhancer region led to a dramatic reduction in expression of BIN1 in microglia, but not in neurons or astrocytes.

"Focusing on genetic variation associated with Alzheimer's disease (AD), we show preferential enrichment in disease risk variants in enhancers that are selectively active in microglia, the major immune cell in the brain," said senior author Dr. Christopher Glass, professor of cellular and molecular medicine at the University of California, San Diego. "This finding substantially extends prior studies linking microglia to late-onset Alzheimer's disease."

The paper was published in the November, 14, 2019, online edition of the journal Science.

Related Links:
University of California, San Diego


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.